Industry News

WHO Endorsement of Simpler Drug Treatment for Blood Pressure Will Improve Treatment Availability for 1 Billion People

George Clinical welcomes the addition of fixed dose combinations (FDCs) of blood pressure (BP) lowering drugs to the World Health Organization (WHO) Essential Medicines List (EML) in response to an application filed by Resolve to Save Lives (RTSL), an initiative of vital strategies, The George Institute and other partners. Adding FDCs of blood pressure lowering […]

Read More

July 31st, 2019

Big and Small Pharma Enjoy a Significant Opportunity to Leverage India for Trials

The Indian subcontinent deserves to be considered by pharmaceutical or biotech firms examining clinical trial locations, and veteran industry players may be surprised to learn India is already a leading destination for global clinical trials with significant growth taking place in the biotech sector.   Prime opportunities exist for all phases of clinical trials due to […]

Read More

July 17th, 2019

George Clinical Awarded Taiwanese Drug License

 SYDNEY, May 15, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted a license to import drugs into the country for clinical trials on behalf of sponsors.  The development will be particularly helpful for small to mid-sized clinical trial clients who do not […]

Read More

May 14th, 2019

EPS International and George Clinical Form Strategic Partnership for the Asia-Pacific Region

Sydney, Australia, April 24, 2019 – EPS International Holdings Co., Ltd. (HQ: Tokyo, Japan; Representative Director and President: Hisashi Tanaka; “EPSI” hereafter) and George Clinical Pty Ltd (HQ: Sydney, Australia; Executive Chairman: Glenn Kerkhof; “George Clinical” hereafter) announced today that they have reached an agreement on a strategic partnership that will enhance their combined service offerings […]

Read More

April 24th, 2019

George Clinical Client Noxopharm Announces Chemotherapy Enhancement Program Expansion

Noxopharm, a clinical-stage Australian drug development company currently working with George Clinical, is seeking to establish Veyonda®, an innovative dosage formulation of the experimental anti-cancer drug idronoxil, as “an essential adjunct to all forms of radiotherapy in the treatment of prostate cancer, both late-stage and early-stage prostate cancer,” according to an announcement last week. Through […]

Read More

April 20th, 2019

George Clinical Congratulates Parent Company The George Institute For Global Health For Securing $12 Million To Tackle Worlds Biggest Killers

[Sydney, Australia] George Clinical congratulates its parent company, The George Institute for Global Health for securing $12 million from the National Health and Medical Research Council (NHMRC), Australia’s peak funding body for medical research. These grants will support The Institute’s scientific leaders to improve the lives of people living with chronic kidney disease, septic shock […]

Read More

February 12th, 2019

Taiwan’s Pragmatic Timelines Make it a ‘Top-Tier’ Country for MRCTs

George Clinical welcomes The Taiwan Food and Drug Administration’s (TFDA) recent clarified timelines for approval of a general Clinical Trial Authority (CTA) at 45 calendar days. The announcement, released by the TFDA in October, adds to the suite of attractive options to expedite clinical trial regulatory approval timelines in Taiwan. This includes the existing 15 […]

Read More

January 8th, 2019

Established Investigator Networks Are Central to the Strength of the Clinical Trial Environment

The importance of securing strong, long-standing investigator networks with leading research hospitals and clinics is critical to the continued growth of the clinical trial environment in countries such as Taiwan, says Evon Hui, Head of Business Operations, East Asia. Over the past 15 years, George Clinical has cultivated an enviable network of MOUs that have […]

Read More

January 6th, 2019

George Clinical Scientific Leader Jason Chandler Sees Approval of New Therapy

George Clinical welcomes the decision by the FDA to approve the delivery of CAR-T therapy in a partnership between Methodist Healthcare, and George Clinical Scientific Leader, Dr. Jason Chandler of West Cancer Center. Car-T therapies are at the cutting edge of treatment for a range of cancers. The recent announcement by the FDA, West Cancer […]

Read More

January 4th, 2019

Heart Health Research Center provides extensive research training and investigator networks to leading CRO George Clinical

Beijing, November 13, 2018 – George Clinical, a leading clinical research organization (CRO) in the Asia-Pacific region, has continued its involvement and collaboration with the Heart Health Research Center (HHRC), further developing the depth and quality of investigator networks. The HHRC, a collaborative initiative developed by Cardio Union, an emerging multi-disciplinary healthcare organization and the […]

Read More

December 6th, 2018

Join our Mailing List

Add George Clinical to your network